Dashboard
Manage Tickers

OCGNOcugen, Inc.

Nasdaq ocugen.com


$ 1.70 $ -0.11 (-6.08 %)    

Tuesday, 14-May-2024 16:05:34 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 445.88 $ 2.85 (0.64 %)
DIA $ 395.58 $ 1.12 (0.28 %)
SPY $ 523.16 $ 2.39 (0.46 %)
TLT $ 90.86 $ 0.51 (0.56 %)
GLD $ 218.12 $ 1.83 (0.85 %)
$ 1.7
$ 1.74
$ 0.00 x 0
$ 0.00 x 0
$ 1.68 - $ 1.81
$ 0.35 - $ 2.11
8,835,124
na
437.3M
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 04-16-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-21-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-05-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 03-19-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-22-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-15-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-11-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-11-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-12-2015 06-30-2015 10-Q
37 05-14-2015 03-31-2015 10-Q
38 03-27-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ocugen-q1-2024-gaap-eps-005-beats-006-estimate-sales-1014m-up-from-443000k-yoy
Ocugen Q1 2024 GAAP EPS $(0.05) Beats $(0....
05/14/2024 11:03:15

why-perficient-shares-are-trading-higher-by-around-53-here-are-20-stocks-moving-in-mondays-mid-day-session
Why Perficient Shares Are Trading Higher B...
05/06/2024 16:32:34

Core News & Articles
Why Clever Leaves Holdings Shares Are Trad...
04/29/2024 17:04:01

ocugen-announces-ocu400-modifier-gene-therapy-phase-12-data-presentation-at-retinal-cell-and-gene-therapy-innovation-summit-2024
Ocugen Announces OCU400, Modifier Gene The...
04/29/2024 10:47:57

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commerciali...

ocugen-says-it-will-present-on-modifier-gene-therapy-platform-at-association-for-research-in-vision-and-ophthalmology-2024-annual-meeting
Ocugen Says It Will Present On Modifier Ge...
04/26/2024 10:36:41

alphabet-to-rally-around-14-here-are-10-top-analyst-forecasts-for-monday
Alphabet To Rally Around 14%? Here Are 10 ...
04/22/2024 12:32:56

key-takeaways-from-ocugen-analyst-ratings
Key Takeaways From Ocugen Analyst Ratings
04/22/2024 12:01:19

chardan-capital-maintains-buy-on-ocugen-raises-price-target-to-5
Chardan Capital Maintains Buy on Ocugen, R...
04/22/2024 11:47:17

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and raises the price target from $4 to $5.

ocugen-says-it-has-completed-dosing-of-subjects-with-geographic-atrophy-in-cohort-2-of-phase-12-armada-clinical-trial-of-ocu410a-modifier-gene-therapy
Ocugen Says It Has Completed Dosing of Sub...
04/19/2024 11:15:36

Company announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a ...

ocugen-disclosed-positive-scientific-advice-from-the-european-medicines-agency-related-to-the-approval-pathway-for-ocu400modifier-gene-therapy-for-broad-retinitis-pigmentosa-indication
Ocugen Disclosed Positive Scientific Advic...
04/10/2024 11:05:25

why-ocugen-shares-are-trading-higher
Why Ocugen Shares Are Trading Higher
04/08/2024 15:08:18

Ocugen shares are trading higher by 7.7% during Monday's session. The company announced U.S. FDA clearance of the IND amend...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
04/08/2024 12:09:45

ocugen-reveals-us-fda-clearance-of-ind-amendment-to-begin-ocu400-phase-3-clinical-trial---first-gene-therapy-to-enter-phase-3-with-broad-retinitis-pigmentosa-indication
Ocugen Reveals US FDA Clearance Of IND Ame...
04/08/2024 10:34:46

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the oth...

why-ocugen-stock-is-climbing-today
Why Ocugen Stock Is Climbing Today
04/05/2024 19:56:33

Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium ...

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
04/05/2024 16:31:08

ocugen-announces-positive-data-and-safety-monitoring-board-review-and-initiation-of-enrollment-in-medium-dose-for-ocu410-a-modifier-gene-therapy-in-phase-12-armada-study-for-geographic-atrophy
Ocugen Announces Positive Data And Safety ...
04/05/2024 11:06:09

Three subjects with geographic atrophy (GA) were dosed in the Phase 1/2 clinical trial to date. An additional three subjects wi...

why-ocugen-shares-are-popping-off
Why Ocugen Shares Are Popping Off
04/03/2024 15:44:44

Ocugen shares are trading higher by 14% during Wednesday's session. The company provided an update on its business activiti...

signet-jewelers-dave--busters-entertainment-blue-owl-capital-and-other-big-stocks-moving-higher-on-wednesday
Signet Jewelers, Dave & Buster's Entertain...
04/03/2024 14:31:14

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

hc-wainwright--co-reiterates-buy-on-ocugen-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Ocug...
04/03/2024 10:46:38

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price tar...

ocugen-reports-395m-in-cash-cash-equivalents-as-of-dec-31-2023
Ocugen Reports $39.5M In Cash, Cash Equiva...
04/02/2024 12:06:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION